The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN ...

The findings add to other research showing a lower risk of obesity-related cancers in patients taking GLP-1 drugs, a class of ...

GLP-1 weight-loss drugs are reshaping dairy demand by curbing cravings for processed, fatty, and sugary products, fueling a ...

In patients with T2D, GLP-1s don’t increase the risk for acute pancreatitis, mitigate the risk for complications in those who ...

The health services arm of The Cigna Group CI, Evernorth, recently introduced a pharmacy benefit offering designed to enhance ...

Adults with obesity using a GLP-1 have a similar risk for obesity-related cancers as those who undergo bariatric surgery, ...

Novo Nordisk's limited-time coupon on Wegovy was simultaneously promoted by telehealth companies Ro and Wegovy ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

Glucagon-like peptide 1 receptor agonist treatment is not associated with an increased risk for psychiatric adverse events or worsening depressive symptoms.

Unless you are from another planet, you’ve heard all about the new weight loss medications taking the world by storm. These ...

Glucagon-like peptide-1 receptor agonists may cut the risk of obesity-related cancer in patients being treated for diabetes and obesity.

There is growing evidence that Ozempic and other GLP-1 receptor agonist drugs might help people drink less alcohol, but more research is needed.